Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Mimedx (MDXG) EBIAT (2016 - 2026)

Mimedx's EBIAT history spans 16 years, with the latest figure at -$10.9 million for Q1 2026.

  • On a quarterly basis, EBIAT fell 254.63% to -$10.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $30.7 million, a 23.19% decrease, with the full-year FY2025 number at $48.6 million, up 15.67% from a year prior.
  • EBIAT hit -$10.9 million in Q1 2026 for Mimedx, down from $15.2 million in the prior quarter.
  • Over the last five years, EBIAT for MDXG hit a ceiling of $62.7 million in Q4 2023 and a floor of -$10.9 million in Q2 2022.
  • Historically, EBIAT has averaged $7.1 million across 5 years, with a median of $7.4 million in 2024.
  • Biggest five-year swings in EBIAT: plummeted 510.91% in 2022 and later surged 15242.03% in 2023.
  • Tracing MDXG's EBIAT over 5 years: stood at -$414000.0 in 2022, then surged by 15242.03% to $62.7 million in 2023, then crashed by 88.13% to $7.4 million in 2024, then soared by 104.24% to $15.2 million in 2025, then plummeted by 171.49% to -$10.9 million in 2026.
  • Business Quant data shows EBIAT for MDXG at -$10.9 million in Q1 2026, $15.2 million in Q4 2025, and $16.7 million in Q3 2025.